Lazcluze (lazertinib tablets - Janssen) — Cigna
Non-Small Cell Lung Cancer (locally advanced or metastatic) with EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an approved test, when used in combination with Rybrevant (amivantamab-vmjw intravenous infusion)
Initial criteria
- Patient age ≥ 18 years
- Patient has locally advanced or metastatic disease
- Patient has EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an approved test
- Medication is used in combination with Rybrevant (amivantamab-vmjw intravenous infusion)
Approval duration
1 year